Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma

Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma

Glioblastoma is the most common primary central nervous system malignancy and has a poor prognosis. Standard first-line treatment, which includes surgery followed by adjuvant radio-chemotherapy, produces only modest benefits to survival1,2. Here, to explore the feasibility, safety and immunobiologic...

Full beskrivning

Bibliografiska uppgifter
Huvudupphovsmän: Schalper, K.A. (Kurt A.), Rodriguez-Ruiz, M.E. (María Esperanza), Diez-Valle, R. (Ricardo), López-Janeiro, Á. (Álvaro), Porciuncula, A. (Angelo), Idoate, M.A. (Miguel Ángel), Inoges, S. (Susana), Andrea, C.E. (Carlos Eduardo) de, Lopez-Diaz-de-Cerio, A. (Ascensión), Tejada-Solis, S. (Sonia), Berraondo, P. (Pedro), Villarroel-Espindola, F. (Franz), Choi, J. (Jungmin), Gurpide, A. (Alfonso), Giraldez, M. (Miriam), Goicoechea, I. (Iosune), Gallego-Perez-Larraya, J. (Jaime), Fernandez-Sanmamed, M. (Miguel), Perez-Gracia, J.L. (Jose Luis), Melero, I. (Ignacio)
Materialtyp: info:eu-repo/semantics/article
Språk:eng
Publicerad: Nature Publishing Group 2024
Ämnen:
Materias Investigacion::Ciencias de la Salud::Oncología
Glioblastoma
Neoadjuvant nivolumab
Länkar:https://hdl.handle.net/10171/68722

Liknande verk

Liknande verk